U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Prostate Carcinoma

MedGen UID:
1757847
•Concept ID:
C5419210
•
Neoplastic Process

Definition

Prostate carcinoma that is not amenable to surgical resection. [from NCI]

Professional guidelines

PubMed

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Patel P, Alrifai D, McDonald F, Forster M; AstraZeneca UK Limited
Br J Cancer 2020 Dec;123(Suppl 1):18-27. doi: 10.1038/s41416-020-01071-5. PMID: 33293672Free PMC Article
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430
Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ, Sheinfeld J
Curr Treat Options Oncol 2005 Sep;6(5):367-77. doi: 10.1007/s11864-005-0040-z. PMID: 16107240

Recent clinical studies

Etiology

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K
Jpn J Clin Oncol 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. PMID: 36484294
Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT, Kao CJ, Wolf M, DeGregorio MW
Hum Vaccin Immunother 2014;10(11):3383-93. doi: 10.4161/hv.29836. PMID: 25483673Free PMC Article
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413

Diagnosis

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
Shamim SA, Kumar N, Arora G, Kumar D, Pathak A, Thakkar A, Sikka K, Singh CA, Kakkar A, Bhalla AS
Clin Nucl Med 2023 Nov 1;48(11):e509-e515. doi: 10.1097/RLU.0000000000004868. PMID: 37812520
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K
Jpn J Clin Oncol 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. PMID: 36484294
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS, Beltran H, Lilenbaum R, Bergsland E
Am Soc Clin Oncol Educ Book 2015:92-103. doi: 10.14694/EdBook_AM.2015.35.92. PMID: 25993147
Prostatic carcinosarcoma: case report and review of literature.
Nazeer T, Barada JH, Fisher HA, Ross JS
J Urol 1991 Nov;146(5):1370-3. doi: 10.1016/s0022-5347(17)38099-0. PMID: 1942296

Therapy

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C, Wang M, Xu C, Li B, Chen J, Chen J, Wang Z
J Immunol Res 2021;2021:8970173. Epub 2021 Nov 28 doi: 10.1155/2021/8970173. PMID: 34877360Free PMC Article
Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT, Kao CJ, Wolf M, DeGregorio MW
Hum Vaccin Immunother 2014;10(11):3383-93. doi: 10.4161/hv.29836. PMID: 25483673Free PMC Article
Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E
Cancer Metastasis Rev 2013 Dec;32(3-4):585-602. doi: 10.1007/s10555-013-9439-3. PMID: 23690170
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413

Prognosis

The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS, Beltran H, Lilenbaum R, Bergsland E
Am Soc Clin Oncol Educ Book 2015:92-103. doi: 10.14694/EdBook_AM.2015.35.92. PMID: 25993147
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T
Int J Clin Oncol 2015 Feb;20(1):35-44. Epub 2014 Feb 20 doi: 10.1007/s10147-014-0674-6. PMID: 24553861
Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E
Cancer Metastasis Rev 2013 Dec;32(3-4):585-602. doi: 10.1007/s10555-013-9439-3. PMID: 23690170
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413

Clinical prediction guides

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T
Int J Clin Oncol 2015 Feb;20(1):35-44. Epub 2014 Feb 20 doi: 10.1007/s10147-014-0674-6. PMID: 24553861
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430
The role of radical cystectomy in patients with clinical T4b bladder cancer.
Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM
Urol Oncol 2011 Mar-Apr;29(2):157-61. Epub 2010 Apr 24 doi: 10.1016/j.urolonc.2009.12.015. PMID: 20456984Free PMC Article
Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate.
Kwon ED, Loening SA, Hawtrey CE
J Urol 1991 Mar;145(3):524-31. doi: 10.1016/s0022-5347(17)38387-8. PMID: 1997703

Recent systematic reviews

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...